Previous Close | 0.0062 |
Open | 0.0067 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0065 - 0.0069 |
52 Week Range | 0.0065 - 0.0300 |
Volume | |
Avg. Volume | 147,668 |
Market Cap | 2.714M |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings Date | Feb 01, 2024 - Feb 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for GBLX
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model.
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson's disease. China is an increasingly important pharmaceutical market with cultural acceptance of plant-based formulations, which is a good fit for Gb Sciences' drug candidates.
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, issued a letter to shareholders today from President, Chief Science Officer, and Director Dr. Andrea Small-Howard and Chairman and CEO John Poss summarizing key developments from 2022 and providing strategic plans for 2023.